Importantly, the physiological relevance of SRPK1 for angiogenesis has been demonstrated, as injection of an SRPK1/2 inhibitor reduced it in a mouse model of retinal neovascularization, suggesting that targeting AS through their upstream regulator could be a potential tool to target pathological angiogenesis in cancer [48]. The gene discussed is SRPK1; the disease is cancer.